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Abstract
Background A new prolonged-release formulation of potassium citrate and potassium bicarbonate, ADV7103, has been shown
to improve metabolic control, palatability, and gastrointestinal safety in patients with distal renal tubular acidosis (dRTA) when
compared to standard of care (SoC) treatments. The present work evaluates safety and efficacy of ADV7103 during 24 months.
Methods Thirty pediatric and adult patients were included in an open-label extension study after a phase II/III trial. Safety and
tolerability were assessed. Plasma bicarbonate and potassium levels, as well as urine parameters, were evaluated over time. Acceptability,
adherence, and quality of life were also assessed. The evolution of clinical consequences of dRTA in the cohort was explored.
Results There were 104 adverse events (AEs) reported, but only 9 gastrointestinal events observed in five patients (17%) were
considered to be related to ADV7103 treatment. There were noAEs leading to treatment discontinuation. Plasma bicarbonate and
potassium levels were in the normal ranges at the different visits, respectively, in 69–86% and 83–93% of patients. Overall
adherence rates were ≥ 75% throughout the whole study in 79% patients. An average improvement of quality of life of 89% was
reported at 24 months of study.
Conclusions Common AEs concerned metabolism and gastrointestinal disorders; the former being related to the disease. Less
than half of the gastrointestinal AEs were related to ADV7103 treatment and they were mostly mild in severity. Metabolic
parameters were maintained in the normal ranges in most patients. Patient satisfaction was high and adherence to treatment was
good and remained stable.
Trial registration number Registered as EudraCT 2013-003828-36 on the 3rd of September 2013.
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Introduction
Treatment of distal renal tubular acidosis (dRTA), a rare disorder
characterized by hyperchloremic metabolic acidosis, frequently
combined with hypokalemia, aims at correcting biochemical ab-
normalities in plasma, and subsequently maintaining biochemi-
cal parameters within acceptable limits in order to avoid their
clinical consequences [1–7]. Current treatment of dRTA consists
of alkalizing salts that are not licensed for dRTA (with no clinical
development in the disease). Available standard of care (SoC)
treatments present inconvenient dosing schemes, bad taste, fre-
quent gastrointestinal side effects, low treatment adherence, and
sub-optimal efficacy [5]. In a recent retrospective study including
31 Turkish patients, all treated with potassium citrate and/or so-
dium bicarbonate, only 13% of patients presented adequate met-
abolic control in more than 75% of the visits [8]. Additionally,
available formulations are not always adapted to pediatric use.
A neworal granule formulation (ADV7103), which combines
the advantages of potassium citrate and potassium bicarbonate,
provides an effective prolonged release of alkalizing salts
affording a 12-h effect with adequate tolerability [9].
A multicenter, open-label, non-inferiority phase II/III trial, com-
paring ADV7103with SoC treatments in patients with a confirmed
diagnosis of dRTA, has been recently published [10]. Non-
inferiority of ADV7103 versus SoC regarding plasma bicarbonate
levels, a biological marker of dRTA, was shown and its statistical
superiority was demonstrated. The number of responders with nor-
mal mean plasma bicarbonate values was significantly increased
when switching to ADV7103, reaching a response rate of 90%,
while it was of 43% previously with SoC. Plasma potassium levels
were in the normal range in 83% of patients and significant im-
provement of other parameters, such as urine calcium/citrate ratio,
palatability, and gastrointestinal tolerability, was also reported [10].
The aim of the present study was to assess safety, tolera-
bility, and efficacy of ADV7103, as well as to evaluate adher-
ence to treatment in adult and pediatric patients with dRTA
after 24 months of treatment. Other clinical outcomes were
investigated, including changes in nephrocalcinosis,
nephrolithiasis, estimated glomerular filtration rate (eGFR),
bone remodeling, rickets, osteomalacia, and growth in chil-
dren, along with treatment acceptability and quality of life.
Methods
Study design and patient population
At the end of the previous phase II/III study [10], all patients
with dRTA who had participated and completed the study
were invited to participate in a multicenter, single-arm,
open-label, follow-up study (EudraCT 2013-003828-36).
Adults (18 to 55 years old), adolescents (12 to 17 years old),
children (4 to 11 years old), and infants and toddlers (6months
to 3 years old) were enrolled to continue their treatment with
ADV7103 for at least 24 months at the optimal dose previ-
ously determined and further adapted if required. ADV7103
consists of prolonged-release granules, presented in 8 mEq
and 24 mEq sachets containing roughly one part of potassium
citrate and two parts of potassium bicarbonate [9]. The total
daily dose was divided in two intakes, one in the morning and
another in the evening, including one or several sachets. The
granules in each sachet were swallowed with a glass of water
or taken in several portions with small amounts of soft food
(e.g., mixed fruits, yoghurt), without chewing or crushing.
Exclusion criteria were unusual additional proximal tubular
signs, hyperkalemia (plasma potassium > 5.0 mmol/L), mod-
erate or severe kidney impairment (eGFR < 45 mL/min/1.73
m2), or any other condition that could be negatively affected
by the study medication or that could affect the study medi-
cation. Patients receiving potassium-sparing diuretics,
angiotensin-converting enzyme inhibitors, angiotensin II re-
ceptor antagonists, or tacrolimus were also ruled out. Study
visits were scheduled at baseline (last visit of phase II/III trial)
and after 3, 6, 12, 18, and 24 months of treatment (Fig. 1).
Thereafter, one visit per year was scheduled for patients con-
tinuing beyond the 24 months (not reported in the present
publication).
Safety and tolerability
The primary objective of the study was to evaluate the long-
term safety of ADV7103 as measured by the occurrence of
adverse events (AEs). Numbers and percentages of patients
presenting AEs were tabulated by body system and preferred
term, according to the Medical Dictionary for Regulatory
Activities (MedDRA, Version 18.0). Severity of the adverse
events was determined. Abnormal values on vital signs, ECG
parameters, physical examination, and laboratory data were
also recorded during the course of the study.
Blood parameters
Plasma bicarbonate and potassium levels were assessed at
each study visit. They were measured in blood samples gen-
erally drawn before first morning dose of treatment. Metabolic
acidosis was considered when plasma bicarbonate level was
below the normal range defined by the local laboratory (lower
boundary was generally 20 to 22 mmol/L, depending on the
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age of the patients) and hypokalemia was considered when
plasma potassium level was below the normal range defined
by the local laboratory (generally 3.5 mmol/L, but could be as
low as 3.1 mmol/L for pediatric patients). Details about
methods and normal ranges are provided as supplementary
information.
Urine parameters and renal exploratory evaluations
Urine excretion parameters, crystalluria, and eGFR were mea-
sured at each study visit. Hypercalciuria was considered when
urine calcium/creatinine excretion ratio (UCa/UCr,
mmol/mmol) was above the corresponding age-specific nor-
mal range [11, 12] and hypocitraturia was considered when
urine citrate/creatinine excretion ratio (UCi/UCr,
mmol/mmol) was below the corresponding age-specific nor-
mal range [13] (see Supplementary Information). Increased
risk of lithogenesis was considered when the urine calcium/
citrate excretion ratio (UCa/UCi, mmol/mmol) was above the
threshold for risk of lithogenesis of 3 mmol/mmol [14].
Positive crystalluria was defined as the presence of at least
one crystal species. The presence of nephrocalcinosis and
nephrolithiasis was evaluated at baseline and after 24 months
of study.
Adherence to treatment
Adherence was estimated based on accountability of study
drug retrieved. The proportion of treatment that had been tak-
en versus what should have been taken was calculated.
Adherence was indicated at each study visit up to 24
months as one of four possible adherence categories: excellent
(> 90%), good (75–90%), average (50–74%), and poor (<
50%). In some particular cases, when drug accountability
was not possible (e.g., the patient did not bring the empty
treatment boxes), the investigators could class the patient in
one of the four categories on the basis of laboratory results and
interview of the patient and their parents.
Growth parameters, bone remodeling, and other
exploratory evaluations
Height, weight, and bodymass index (BMI) were evaluated at
each study visit and the corresponding z-scores were
determined [15] according to WHO standards [16, 17], con-
sidering age and sex. Values were considered normal when
they were within the ± 2SD range.
Bone mineral density (BMD, g/cm2) was measured sepa-
rately for three skeletal regions (spine, hip, and whole body) at
baseline and after 24 months of treatment and the correspond-
ing z-scores were provided. The z-score was considered below
the expected range for a value ≤ − 2.0 according to recom-
mendations of the International Society for Clinical
Densitometry (ISCD) [18]. An overall clinical interpretation
was provided.
Specific blood markers were analyzed at each study visit,
by a central laboratory (bone alkaline phosphatases, 1,25-di-
hydroxy-vitamin D, and parathyroid hormone) or by local
laboratories (phosphate, calcium, and 25-hydroxy-vitamin
D). Details about the methods used and normal ranges consid-
ered by each local laboratory are provided as supplementary
information.
The presence of rickets and osteomalacia was evaluated at
baseline and after 24 months of study, based on clinical signs,
such as diffuse bone and joint pain, myalgia, muscle weak-
ness, abnormal posture, and abnormal stature, and biochemi-
cal signs, including abnormal levels of alkaline phosphatases,
calcium, and phosphate.
Quality of life and acceptability
Quality of life (QoL) and treatment acceptability were ex-
plored through questions about the perception of the improve-
ment of different parameters when compared to SoC treat-
ments taken previously. They were assessed by the patients
(or their parents) with 100-mm visual analogue scales (VAS,
where 0 meant “No improvement at all” and 100 meant
“Extremely high improvement”). Improvement of QoL was
evaluated for patients after 6 and 24 months and for their
parents after 24 months of treatment. In order to evaluate
acceptability, improvement of the number of daily intakes,
appropriateness of the formulation, taste, efficacy, and gastro-
intestinal tolerability, were assessed at the 24-month visit.
Statistical methods
The primary endpoint was the number/proportion of patients
presenting AEs during the course of the study, including the
Fig. 1 Study design
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incidence and severity of these events. The safety analysis
(SA) set included all patients who received at least one dose
of study drug.
The efficacy analysis (EA) set included all patients who
received at least one dose of study drug and who had at least
one efficacy assessment. However, subgroup analyses were
performed with patients for whom it could be ascertained that
blood samples were drawn before first morning dose. For
plasma potassium determinations, patients with hemolyzed
blood samples were tagged in order to perform subgroup anal-
yses excluding them. The number/proportion of patients pre-
senting normal values for plasma or urine parameters was
calculated at each time point.
The QoL analysis (QA) set included all patients who re-
ceived at least one dose of study drug and who had at least one
QoL assessment.
Safety, efficacy, adherence, and QoL data and their change
from baseline (when appropriate) were summarized by age
group, overall, and over time using descriptive statistics.
Statistical analyses were generated using SAS software,
Version 9.4, of the SAS System for Windows (SAS is a reg-
istered trademark of SAS Institute Inc., Cary, NC, USA).
Results
A total of 30 patients (93.8% of the patients who completed
the pivotal study), all with primary dRTA, were enrolled
(Table 1) in 12 different centers in France, Serbia, and
Slovakia. One patient dropped out after 12 months of treat-
ment for personal reasons. Among the patients enrolled,
66.7% presented hearing impairment. One toddler had hypo-
kalemia, two patients (one child and one adult) had
osteopenia, and one child had polyuria.
Adverse events and safety and tolerability
observations
A total of 27 patients (90%) experienced the 104 AEs ob-
served during the course of the study: 20 AEs in four adult
patients (67%), 37 AEs in eight adolescents (100%), 37 AEs
in twelve children (92%), and 10 AEs in three toddlers
(100%), most of them (83 AEs in 23 patients) of mild inten-
sity. As shown in Table 2, there were 21 metabolism and
nutrition AEs in 14 patients (47%), 20 gastrointestinal AEs
in 12 patients (40%), and 29 infections and infestations in 10
patients (33%). A low frequency of AEs was reported (< 10
AEs) in the remaining body systems.
There were no AEs leading to treatment discontinuation
and no deaths reported during the study. Four serious AEs
were reported in four patients (13.3%), all considered unrelat-
ed to treatment: renal colic, acute gastritis, wisdom teeth
removal, and rotavirus gastroenteritis, which resolved within
the following days without modification of the dose.
Only nine AEs noted in five patients (16.7%), all gastroin-
testinal AEs, were considered related to the treatment: three
events of diarrhea in one patient, two events of abdominal pain
in two children, and single events of dyspepsia, upper abdom-
inal pain, gastrointestinal disorder, and gastrointestinal pain.
They were of mild or moderate severity and resolved without
discontinuation of the treatment. Only one of them (gastroin-
testinal disorder in an adolescent) required a dose adjustment,
which was without consequence on plasma and urine meta-
bolic parameters of the patient. Concomitant treatments were
provided in certain cases, such as intestinal absorbent clay for
diarrhea, gastrointestinal pain and gastrointestinal disorder,
antacid for abdominal pain, and an antispastic for dyspepsia.
There were no clinically significant abnormalities in vital
signs. No episodes of hyperkalemia were reported and there
were no ECG abnormalities, including those classically asso-
ciated with hyperkalemia. Physical examination findings were
normal except for a non-clinically significant weight gain at
month 18 in a child and a molluscum contagiosum in another
child, both declared as unrelated to treatment.
Among the abnormalities that were considered to be clini-
cally significant after clinical laboratory evaluations, most
were cases of low blood levels of 25-hydroxyvitamin D (three
adolescents, two children, and one infant). At baseline, the
overall mean ± SD blood 25-hydroxy-vitamin D level was
51.5 ± 33.7 nmol/L but was as low as 20 nmol/L in one of
the patients. At the 24-month visit, mean ± SD was 58.9 ±
20.8 nmol/L and the lowest value observed was 27.5 nmol/L.
Sixty percent of the patients received vitamin D supplemen-
tation at some time point during the study. One child had
clinically significant high erythrocyte and leucocyte levels
on microscopic analysis of urine.
Evolution of the dose
The overall mean ± SD dose at baseline was 107.7 ± 57.4
mEq/day and increased up to 117.0 ± 67.6 mEq/day after 24
months of treatment. The overall mean ± SD dose per body
weight was 3.4 ± 1.7 mEq/kg/day at baseline and 3.2 ± 1.6
mEq/kg/day at month 24. This represented an average dose of
2.3 ± 1.3 mEq/kg/day in the adult group, 2.6 ± 1.7 mEq/kg/
day in the adolescent group, 3.4 ± 1.3 mEq/kg/day in the child
group, and 4.8 ± 2.0 mEq/kg/day in the infant/toddler group,
respectively, by month 24.
Metabolic parameters and renal consequences of
dRTA
The evolution of overall mean plasma bicarbonate and plasma
potassium levels is shown in Fig. 2. Similar results were ob-
tained in the subgroup analyses. At 24months, overall mean ±
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SD plasma bicarbonate levels were 22.7 ± 3.1 mmol/L con-
sidering all available data (N = 29) and 22.8 ± 2.9 mmol/L
when considering only patients for whom blood samples were
drawn before first morning dose (N = 24). Plasma potassium
levels were 3.7 ± 0.4 mmol/L considering all available data (N
= 29) and 3.8 ± 0.3 mmol/L considering only patients for
whom blood samples were drawn before first morning dose
and with non-hemolyzed samples (N = 23). Plasma bicarbon-
ate was in the normal range in 63% of patients at baseline and
in 69 to 86% of patients throughout the 24 months of treat-
ment. Only one adult patient was considered to have clinically
significant metabolic acidosis at month 18 and month 24.
Plasma potassium was in the normal range in 90% of patients
at baseline and in 83 to 93% of patients at following visits.
One child and an adolescent at month 12 and an adult at month
24 were considered to present clinically significant
hypokalemia.
The evolution of overall mean urine parameters is shown in
Fig. 3. The overall mean ± SD UCi/UCr ratio was 0.2 ± 0.2
mmol/mmol at 24 months (change from baseline of − 0.01 ±
0.18 mmol/mmol), with values generally above 0.3 mmol/
mmol in infants/toddlers and below 0.1 mmol/mmol in adults.
At the different visits, 9 to 17 patients presented
hypocitraturia. Overall mean ± SD UCa/UCr ratio was 0.3 ±
0.2 mmol/mmol at 24 months (change from baseline of − 0.06
± 0.14 mmol/mmol). With the exception of one or two cases
of hypercalciuria (affecting 5 different patients in all) at each
time point, patients presented values of UCa/UCr within the
normal range for their age throughout the 24 months. The
overall mean ± SD UCa/UCi ratio was 7.4 ± 11.5 mmol/
mmol at 24 months (change from baseline of 0.6 ± 8.9
mmol/mmol). The percentage of patients with UCa/UCi ratio
below the threshold for risk of lithogenesis was 45% at base-
line and ranged from 48 to 63% at all other visits.
At baseline, 9 patients had a positive crystalluria result.
Amorphous carbonated calcium phosphate (ACCP) crystals
were observed in 8 patients and an unknown type of crystal
was reported in one infant. After 24 months of treatment,
ACCP crystals were reported in 7 cases out of the 8 observed
at baseline; ammonium hydrogen urate crystals were reported
in three cases; brushite, struvite, and rare calcium oxalate
crystals were reported each in one case.
Only six patients (20.7%) presented nephrolithiasis at base-
line, from which one child recovered after 24 months of treat-
ment. A total of 25 patients (86.2%), 5 adults, 6 adolescents,
13 children, and 1 toddler at baseline, and 28 patients (96.6%),
5 adults, 7 adolescents, 13 children, and 3 toddlers at month
24, presented nephrocalcinosis.
Mean ± SD values of eGFR were 116.2 ± 19.8, 106.5 ±
12.8, 121.2 ± 19.2, and 128.0 ± 11.4 mL/min/1.73 m2 in
adults, adolescents, children, and toddlers, respectively, after
24 months of treatment. Considering paired patient data, the
Table 1 Patient disposition and summary of demographic data by age group and overall
Adults Adolescents Children Infants and toddlers Overall
N enrolled 6 8 13 3 30
N (%) females 4 (67%) 6 (75%) 7 (54%) 0 (0%) 17 (57%)
N (%) males 2 (33%) 2 (25%) 6 (46%) 3 (100%) 13 (43%)
Age (Y)
Median (range) 19.3 (18.8, 21.6) 14.0 (12.7, 17.3) 6.5 (4.6, 11.6) 3.4 (2.1, 3.8) 10.3 (2.1, 21.6)
Weight (kg)
Median (range) 59.3 (50.2, 87.0) 44.3 (41.0, 57.7) 21.5 (12.4, 50.0) 15.3 (12.0, 20.2) 41.1 (12.0, 8 7.0)
Weight (z-score) NA NA
Median (range) − 0.2a (− 2.5, 2.6) 0.1 (− 0.3, 1.8) − 0.1a (− 2.5, 2.6)
Height (cm)
Median (range) 160 (149, 169) 161 (146, 170) 116 (92, 146) 101 (86, 102) 141 (86, 170)
Height (z-score)
Median (range) − 1.4b (− 1.8, − 1.0) − 0.4 (− 1.2, 1.5) − 0.6 (− 3.3, 0.8) 0.0 (− 0.9, 0.5) − 0.5b (− 3.3, 1.5)
BMI (kg/m2)
Median (range) 23.9 (19.9, 30.5) 16.9 (15.5, 24.2) 16.0 (12.8, 23.5) 16.4 (15.0, 19.4) 17.3 (12.8, 30.5)
BMI (z-score)
Median (range) 0.7b (− 0.8, 2.2) − 1.1 (− 2.0, 1.3) 0.1 (− 2.3, 3.3) 0.4 (− 0.4, 2.8) − 0.1b (− 2.3, 3.3)
N completed 5 8 13 3 29
N number of patients, Y years
aWeight z-scores available for patients ≤ 10Y
bHeight and BMI z-scores available for patients ≤ 19Y
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overall mean ± SD change from baseline in eGFRwas of − 5.6
± 24.3 mL/min/1.73 m2, with mildly decreased kidney func-
tion in a single patient at the last study visit (there was already
one at baseline).
Treatment adherence, improvement of quality of life,
and acceptability
Treatment adherence values over time are shown in Table 3.
Adherence rates were ≥ 75% in 79.3% of patients remaining
in the study at month 24 (100% of adults, 62.5% of adoles-
cents, 84.6% of children, and 2 out of the three toddlers,
respectively).
As shown in Fig. 4a, the change of alkalizing treatment
from SoC to ADV7103 led to an overall average improvement
in the QoL of the patients of 80.7% at month 6 and of 88.9% at
month 24, and of their parents of 89.6% at month 24.
Regarding acceptability, overall scores indicated improve-
ments of 90.2% for the number of daily intakes, 83.9% for
appropriateness of the formulation, 68.6% for taste, 91.2% for
efficacy, and 72.2% for gastrointestinal tolerability (see Fig.
4b).
Growth and bone mineral density
Most patients presented z-scores within the ± 2SD range for
weight, height, and BMI. Among pediatric patients, one child
was below the ± 2SD range for height at baseline (z-score < −
3) but was within range fromM12, with a total increase of 1.8
units after 24 months of treatment. Two children were below
the ± 2SD range for weight at baseline but one of them was
Table 2 Adverse events by body system
Body system Number of adverse events Number of patients with at
least one adverse event
Percentage of patients with
at least one adverse event
Blood and lymphatic system disorders 1 1 3.3
Endocrine disorders 1 1 3.3
Gastrointestinal disorders 20 12 40.0
General disorders and administration site conditions 1 1 3.3
Immune system disorders 1 1 3.3
Infections and infestations 29 10 33.3
Injury, poisoning and procedural complications 2 2 6.7
Investigations 2 2 6.7
Metabolism and nutrition disorders 21 14 46.7
Musculoskeletal and connective tissue disorders 6 6 20.0
Nervous system disorders 3 3 10.0
Kidney and urinary disorders 8 5 16.7
Reproductive system and breast disorders 2 2 6.7
Skin and subcutaneous tissue disorders 5 5 16.7
Surgical and medical procedures 2 2 6.7
TOTAL 104 27 90.0
Fig. 2 Mean (SEM) overall
values of a plasma bicarbonate
and b plasma potassium with
ADV7103 at baseline and after 3,
6, 12, 18, and 24 months of
treatment
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within the ± 2SD range from M6 and the other from M18.
Median height and weight z-scores increased in all pediatric
age groups, with an overall median change (range) of 0.2 (−
0.6, 1.8) for height (n = 23) and 0.3 (− 0.4, 0.8) for weight (n =
11).
There was one case of rickets in a toddler at baseline, which
had recovered at the 24-month visit. No cases of osteomalacia
were observed during the whole study.
Overall clinical interpretation of exploratory bone mineral
density results indicated that 15 (54%) patients presented ab-
normal bone status at baseline. Four of them (two adults, one
adolescent, and one toddler) benefited from a modification of
their bone status from abnormal to normal after 24 months of
treatment. One adolescent had normal status at baseline and
became abnormal at the end of the evaluation period. Median
change from baseline values in spine z-scores was positive in
all age groups, with an overall median change (range) of 0.3
(− 0.9, 1.3).
Discussion
ADV7103 is a prolonged-release oral formulation, which
combines the advantages of potassium citrate and potassium
bicarbonate. Its efficacy in the management of plasma bicar-
bonate levels and its superiority when compared to current
SoC treatments have recently been shown in patients with
dRTA [10].
Among the long-term effects of the disorder, failure to
thrive, rickets, and stunted growth in children, and
osteomalacia/osteopenia in young adults, due to release of
both phosphate and calcium from bone in an attempt to com-
pensate chronic metabolic acidosis [19, 20] are the major bone
issues. These are a direct consequence of metabolic acidosis,
as illustrated in a retrospective study including 95 patients
with primary dRTA by the significant difference in blood
pH values between patients with and without bone disease
(7.32 ± 0.06 vs. 7.37 ± 0.06, p = 0.01) [21], and are corrected
with adequate metabolic control [8].
Adequate growth parameters and BMDwere observed dur-
ing the study. Although most patients were within the ± 2SD
range for height and weight, an overall positive evolution was
shown, with a particularly marked effect on the patients who
were below the range at baseline. Improvement in BMD in
some patients was also observed.
Hypercalciuria is frequent, affecting 15% of patients, as
reported in an international cohort including 340 patients with
dRTA [5]. Supersaturation and precipitation of poorly soluble
calcium salts, due to increased levels of urine calcium excre-
tion together with low citraturia levels in dRTA patients, lead
to progression of nephrocalcinosis and nephrolithiasis, which
have been observed, respectively, in 88% and in 20–42% of
patients (depending on the mutation) [5]. This may impact
Fig. 3 Mean (SEM) overall values of a urine citrate/creatinine ratio, b urine calcium/creatinine ratio, and c urine calcium/citrate ratio with ADV7103 at
baseline and after 3, 6, 12, 18, and 24 months of treatment
Table 3 Number of patients (%) for each adherence category over time
Adherence category Baseline–3 M (N = 30) 3–6 M (N = 29) 6–12 M (N = 30) 12–18 M (N = 29) 18–24 M (N = 29)
Excellent 22 (73.3) 19 (65.5) 22 (73.3) 19 (65.5) 18 (62.1)
Good 6 (20) 7 (24.1) 3 (10) 4 (13.8) 5 (17.2)
Average 1 (3.3) 2 (6.9) 4 (13.3) 5 (17.2) 6 (20.7)
Poor 1 (3.3) 1 (3.4) 1 (3.3) 1 (3.4) 0
N, number of patients; M, months
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kidney function, leading to chronic kidney disease starting
from adolescence [22], and potentially evolving to stage 5
chronic kidney disease/kidney failure. Approximately 30%
of the patients with dRTA present eGFR values < 90 mL/min/
1.73 m2, according to different retrospective cohort studies [5, 8,
22], but in adult patients, the proportion may reach 82% [5]. The
decrease in kidney function in patients with dRTA has been
estimated to be around 3.5 mL/min/1.73 m2 per year in a cohort
of children and young adults [8] and 0.8 mL/min/1.73 m2 per
year in a cohort of adult patients [5]. Higher kidney function is
observed in patients with adequate metabolic control compared
to those not adequately controlled [5].
In a retrospective study including 95 adult and pediatric
patients with dRTA, significantly higher calcium urine levels
were shown in patients with lithiasis when compared to those
without stones [21]. In untreated patients, average UCa/UCr
levels of 1.3 mmol/mmol, approximately 3 to 4 times those of
normal controls, and average UCi/UCr levels below 0.06
mmol/mmol, less than 1/3 of those of normal controls, are
observed [23]. With ADV7103, urine calcium excretion was
controlled and mean UCa/UCr values were maintained at
constant levels around 0.3 mmol/mmol. Citraturia was higher
than that observed in untreated patients and mean UCi/UCr
values around 0.2 mmol/mmol were observed, but
hypocitraturia remained in half of the patients or more.
Compared to current SoC treatments, ADV7103 has been
shown to increase from 20 to 60% the percentage of patients
with UCa/UCi excretion ratios below the threshold considered
for an increased risk of lithogenesis [10] and this percentage
was maintained around 50% throughout the present study.
After 24 months of treatment, the mean UCa/UCi ratio was
7.4 mmol/mmol with ADV7103, while this ratio may reach
average levels of 169 mmol/mmol in untreated patients [23].
The frequency of nephrocalcinosis and nephrolithiasis in
the present study was in agreement with the literature [5]. One
child recovered from nephrolithiasis but nephrocalcinosis was
not shown to be improved during the study. Although its
progression may be prevented, nephrocalcinosis has been re-
ported to be maintained despite limitation of hypercalciuria
[24]. However, more time under ADV7103 treatment would
be required to draw further conclusions. Kidney function
remained normal in the majority of the patients, with mean
Fig. 4 Improvement of a quality
of life at 6 and 24 months, and b
number of intakes, taste,
formulation, efficacy, and
gastrointestinal tolerability at 24
months after change of alkalizing
treatment from SoC to ADV7103
in the different age groups and
overall
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eGFR values > 100 mL/min/1.73m2 in all age groups during
the 24 months of treatment with ADV7103.
Low plasma potassium levels (< 3.5 mmol/L) associated with
dRTA due to renal potassium wasting [19, 25, 26] are correctly
managed with ADV7103 by virtue of its composition in potas-
sium salts [10]. Hypokalemia can cause fatigue, but more impor-
tantly cardiac arrhythmias, paralysis, and even death [27–29].
The results of the present study demonstrate normal bicarbonate
and potassium levels are maintained during the 24 months of
treatment with twice daily administration of ADV7103.
For adequate management, it is important to consider that
dose adjustments are required in order to adapt the amounts of
alkali. As expected, total doses (expressed inmEq/day) increased
due to growth and weight gain, although alkali requirements
(expressed in mEq/kg/day) are reduced with age in patients with
dRTA due to the strongest physiological acid metabolism
occuring in young children compared to adolescents and adults
[21]. The presence of children with plasma bicarbonate values
below the normal range at some time-points could be partially
explained by insufficient dose increases and could indicate that
the frequency of visits during childhood should be higher in order
to best adapt dosing to the evolving needs of the patients. As
suggested by the results of the phase II/III study, the doses pre-
scribed with ADV7103 can be titrated to the optimal dosing,
while with SoC treatment dosing seems to be limited by tolera-
bility and acceptability [10]. Additionally, vitamin D supplemen-
tation was frequently required for prevention or treatment of
hypovitaminosis.
Gastro-intestinal disorders, well-known adverse effect of
alkalizing products, were among the most common AEs ob-
served. Overall, the safety of ADV7103 is very good and the
cases of gastrointestinal AEs were mostly mild in severity and
were reported in few patients (16.7%). No new safety concerns
were raised and the only drop out was without relation to the
treatment.
Present results obtained with ADV7103 confirm the good
acceptability of the product and the adequate adherence to
treatment. The patients and their parents indicated high im-
provement of their QoL. Treatment with ADV7103 continues
in the 29 patients who continued to the end of the 24 months
originally planned.
One of the limitations of the study is that, considering the
small number of patients due to the orphan nature of the dis-
order and the broad range of ages included, most exploratory
evaluations only allowed reporting some interesting observa-
tions regarding improvement in individual patients.
Additionally, patients were already treated before entering
the study and so it was extremely difficult to observe a signif-
icant evolution confirming clinical improvement.
In conclusion, the safety observations over 24 months dur-
ing the extension study in patients with dRTA are consistent
with the known safety of ADV7103. The sustained control of
metabolic acidosis, hypokalemia, and urine parameters,
together with the good treatment acceptability and adherence,
confirms the observations made during the previous short-
term phase II/III trial, reinforcing the safety and efficacy pro-
file of the new drug.
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